JFG
URGN icon

Jefferies Financial Group’s UroGen Pharma URGN Stock Holding History

Jefferies Financial Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$411K – 1694
2025
Q2 		$411K Buy
+30,000
New +$288K ﹤0.01% 948

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Jefferies Financial Group's URGN Position: Q2 2026 in Review

Jefferies Financial Group held its UroGen Pharma (URGN) position steady in Q2 2026 at 2,199,652 shares worth $80.9M. The position accounts for 0.53% of the portfolio, ranked #25.

Jefferies Financial Group first reported a position in URGN in Q1 2024 and has held it in 10 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Jefferies Financial Group held 2,199,652 shares of UroGen Pharma worth $80.9M as of Q2 2026.
  • Jefferies Financial Group left its UroGen Pharma share count unchanged in Q2 2026.
  • UroGen Pharma made up 0.53% of Jefferies Financial Group's portfolio in Q2 2026, its #25 holding.
  • Jefferies Financial Group first reported a position in UroGen Pharma in Q1 2024 and has held it in 10 quarters since.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.